Landscape Capital Management L.L.C. raised its position in Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 88.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79,088 shares of the biopharmaceutical company’s stock after purchasing an additional 37,186 shares during the period. Landscape Capital Management L.L.C. owned 0.23% of Nektar Therapeutics worth $4,788,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in NKTR. Orbimed Advisors LLC bought a new position in shares of Nektar Therapeutics in the first quarter worth $19,786,000. Two Seas Capital LP boosted its stake in Nektar Therapeutics by 8.2% during the third quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock valued at $202,582,000 after buying an additional 253,744 shares during the period. Braidwell LP boosted its stake in Nektar Therapeutics by 112.7% during the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after buying an additional 250,916 shares during the period. Bank of New York Mellon Corp bought a new stake in Nektar Therapeutics during the second quarter valued at $6,706,000. Finally, ACT Capital Partners L.P. purchased a new position in Nektar Therapeutics during the third quarter worth about $5,473,000. 75.88% of the stock is currently owned by hedge funds and other institutional investors.
Nektar Therapeutics Stock Performance
Nektar Therapeutics stock opened at $35.91 on Wednesday. The firm’s fifty day moving average price is $46.93 and its 200-day moving average price is $64.55. The stock has a market cap of $1.23 billion, a P/E ratio of -5.56 and a beta of 1.44. Nektar Therapeutics has a fifty-two week low of $33.40 and a fifty-two week high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.44. The company had revenue of $9.39 million during the quarter, compared to the consensus estimate of $10.27 million. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%. On average, analysts predict that Nektar Therapeutics will post -7.53 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages have weighed in on NKTR. Wedbush decreased their target price on Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 23rd. BTIG Research reaffirmed a “buy” rating and issued a $178.00 price target on shares of Nektar Therapeutics in a report on Friday, October 9th. HC Wainwright reiterated a “buy” rating and set a $185.00 price target on shares of Nektar Therapeutics in a research report on Friday, October 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a research report on Friday, August 28th. Finally, UBS Group began coverage on Nektar Therapeutics in a report on Monday, October 12th. They set a “neutral” rating and a $53.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.33.
Read Our Latest Report on NKTR
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Read More
- Five stocks we like better than Nektar Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR – Free Report).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
